PathMaker Neurosystems Inc. announces selection as 2014 YEi Laureate in the Young Entrepreneurs Initiative competition put on by the French Consulate/Invest in France Agency
Boston, MA (November 1, 2014) – PathMaker Neurosystems Inc. (“PathMaker”) today announced that it was selected as 2014 YEi Laureate in the Young Entrepreneurs Initiative competition. This annual competition, started in 2005 and organized by The Office for Science and Technology at the Embassy of France and the Invest in France Agency, is a program designed to help entrepreneurs establish and grow their business in France and Europe. It provides an intensive training in Boston and Paris and a one week business development immersion in France that will allow Laureates to benefit from an extensive customized business network and connections to the best resources in Europe. PathMaker Neurosystems was chosen as 1 of 3 life science Laureates from over 200 applications participating in this year’s YEi program, and candidates went through two selection processes to determine this year’s winners. “PathMaker is honored and delighted to have been selected as 2014 YEi Laureate, and we are looking forward to the opportunity to accelerate the establishment of our European operations,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “We are focused on obtaining rapid regulatory approval of the world’s first tsDCS-based clinical product, and the support of the French government will greatly facilitate our efforts.”
About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by our company’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology we are developing promises to open up entirely new methods of treating these patients.
Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, email@example.com